Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Mesothelioma

Mesothelioma, Malignant

Adenoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Mesothelial

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Pleural Neoplasms

Lung Diseases

Respiratory Tract Diseases

Malignant Mesothelioma

This is a non-random, multicenter, open label, single agent study. Patients with mailgnanat mesothelioma that has reccured or progressed following chemotherapy, and who qualify for this study, will receive oral milataxel.

Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.

Milataxel

Harvey Pass, M.D.

Philip Bonomi, M.D.

Sarah Mauro

Hedy Kindler, M.D.

Milataxel is a new taxane that may have several advantages over the currently available taxanes. The current study is designed to determine the response rate of oral Milataxel in patients with malignant Mesothelioma. The study specifically targets patients who have recurring or progressive disease following previous chemotherapy.

This is a non-randomized, multicenter, open label, single agent phase II study. Patients with malignant mesothelioma that has recurred or progressed following chemotherapy, and who qualify for this study, will receive milataxel 60 mg/m2 orally on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles. Patients will receive drug for a total of six cycles. Milataxel administration in excess of six cycles will be permitted at the discretion of the Investigator if patients have stable or responding disease.

An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma

A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma

Taxolog Inc.

Harvey Pass, M.D. Chief, Division of Thoracic Surgery and Thoracic Oncology

Spots Global Cancer Trial Database for milataxel

Every month we try and update this database with for milataxel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma	NCT00685204	Mesothelioma	Milataxel	18 Years -	Taxolog Inc.
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma	NCT00685204	Mesothelioma	Milataxel	18 Years -	Taxolog Inc.
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma	NCT00685204	Mesothelioma	Milataxel	18 Years -	Taxolog Inc.

Spots Global Cancer Trial Database for milataxel

Every month we try and update this database with for milataxel cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for milataxel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.